Recruiting

Observational Study

Sponsor:

University Hospital, Basel, Switzerland

Code:

NCT07777744

Conditions

Ventricular Tachycardia (VT)

Premature Ventricular Complexes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The investigators aim to characterize patients presenting with a severe ventricular tachycardia (VT) and premature ventricular complex (PVC)-ablation-related complication including patient characteristics, procedural details and subsequent management of the complication by gathering existing patient-level data.

Conditions

Ventricular Tachycardia (VT)

Premature Ventricular Complexes

Study ID

NCT07777744

Start date

Jul 1, 2024

Status verified date

Aug, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Dec 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Centers : Centers participating in the present collaborative study group. Invitation to participate will be based either upon personal referral of one of the investigator, previous collaboration or based on a meta-analytic review of the literature published on the subject within the past 20 years.
  • Patients: Females and males of >18 years undergoing any type of VT/PVC ablation. While we will accept redo-procedure we will ask for a unique patient-identifier to link procedures belonging to the same patients together.
  • Interventions: VT/PVC ablation (first intervention or re-do) as routinely performed by the participating centers
  • Outcomes: Severe complications, defined as hemodynamic instability requiring mechanical intensive-care management, tamponade, stroke, cardiac arrest, myocardial infarction, phrenic nerve palsies, major bleeding requiring transfusion, vascular or cardiac complication requiring surgery, procedure-related death.
  • Setting: Observational cohort studies, registries, retrospective cohort studies. Data stemming from RCTs (Randomized controlled trials) will not be collected as they likely do not represent a "real-life" setting.
  • Length of follow-up: Peri-procedural complications
  • Years considered: Not limited to a specific time-frame, but to reflect common ablation practices, we will focus on data from the 20 past years.
  • Number of patients provided : No lower limit of patients provided per dataset or ablation volume per year to include high- as well as low-volume centers

Exclusion Criteria:

  • Refusal of the center to participate.
  • Less than 10 procedures available in the dataset (no case reports)
  • Missing essential baseline characteristics, missing collection of sufficient details regarding each complication.

Study Design

Enrollment

15000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Descriptive characterization of patients [ Time Frame: up to 30 days ]

Central Contacts and Locations

Central contacts

Michael Kühne, Prof. Dr. med.

0041 61 265 52 14Michael.kuehne@usb.ch

Locations

Rush University Medical Center

Recruiting

Chicago, Illinois, United States, 60612

Contacts

Henry Huang

312-942-5000henry.huang@bsd.uchicago.edu

University of Michigan

Recruiting

Michigan Center, Michigan, United States, 48109

Contacts

Jackson Liang

734-936-4000liangjac@med.umich.edu

Université Laval

Recruiting

Québec, Canada

Contacts

Jean-Francois Sarrazin

418-656-2131jean-francois.sarrazin@criucpq.ulaval.ca

More Information

Sponsor

University Hospital, Basel, Switzerland

Last update posted

Aug 20, 2026

Last verified

Aug, 2026

Keywords

  • Ablation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University Hospital, Basel, Switzerland on 2026-08-20.